BioFactura Completes Phase I For Late-To-Market Stelara Biosimilar

Firm Aims To File Biosimilar Ustekinumab Candidate In Developed Markets In 2026

 
• By Chloe Kent

BioFactura has completed a successful Phase I trial of its Stelara (ustekinumab) biosimilar BFI-751, which is expected to file in developed markets in 2026.

Hand pushing wooden block signifying phase 1, positioned above blocks signifying phase 2 and 3
Analysts estimate that BioFactura's ustekinumab represents a $50m market opportunity • Source: Shutterstock

More from Biosimilars

More from Products